

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this 27th day of November, 1995.



*Grover F. Fuller Jr.*  
(Signature of person mailing)

Grover F. Fuller Jr.  
(Typed or printed name of person)

PATENT  
PC7851G

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: :  
JOHN E. MACOR, et al. : Examiner: Not yet  
 : assigned  
SERIAL NO.: 08/466,644 :  
FILED: June 6, 1995 : Art Unit: Not yet  
 : assigned  
FOR: INDOLE DERIVATIVES :  
-----

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein makes available to the Patent and Trademark Office the following copending cases cited by the applicant(s), copies of the claims were enclosed with their corresponding PCT published applications, cited to the USPTO in the present application.

Our Ref. No. PC 8096A  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/US92/08306  
Publication No.: WO 93/11106  
U.S. Serial No. 08/244,043  
Filed: May 20, 1994  
For: Indole Derivatives

Our Ref. No. PC 8237B  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/US93/01667  
Publication No.: WO 93/18032  
U.S. Serial No. 08/284,662  
Filed: August 19, 1994  
For: Indole Derivatives As 5-HT1 Agonists

3/91  
M.2  
(10/2)

95 DEC 28 AM 9:49  
GROUP: 120

Our Ref. No. PC 8239A  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/US93/01967  
Publication No.: WO 93/20073  
U.S. Serial No. 08/295,798  
Filed: September 16, 1994  
For: Indole Derivatives

Our Ref. No. PC 8260A  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/US93/01807  
Publication No.: WO 93/21180  
U.S. Serial No. 08/295,792  
Filed: September 14, 1994  
For: Acylindole Derivatives As 5-HT1 Agonists

Our Ref. No. PC 8261  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/EP93/00867  
Publication No.: WO 93/21178  
U.S. Serial No. 08/307,566  
Filed: September 21, 1994  
For: Indole Derivatives as 5-HT1-Like Agonists

Our Ref. No. PC 7907A  
In Re Application Of: Jolanta Nowakowski  
U. S. Patent No. 5,409,941  
Issued: April 25, 1995  
For: 5-Heteroylindole Derivatives

Our Ref. No. PC 8270  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/EP93/00738  
Publication No.: WO 93/21177  
U.S. Serial No. 08/313,106  
Filed: October 6, 1995  
For: Indole Derivatives as 5-HT1-Like Agonists

Our Ref. No. PC 8364A  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/US93/09790  
Publication No.: WO 94/10171  
U.S. Serial No. 08/424,357  
Filed: April 27, 1995  
For: 5-Arylindole Derivatives

Our Ref. No. PC 8428  
In Re Application Of: Martin James Wythes  
Int'l Appl'n No.: PCT/EP94/01121  
Publication No.: WO 94/24127  
U.S. Serial No. 08/532,573  
Filed: October 20, 1995  
For: Indole Derivatives as 5-HT1-Like Agonists for Use  
in Migraine

Our Ref. No. PC 8550  
In Re Application Of: John E. Macor et al.  
Int'l Appl'n No.: PCT/IB94/00195  
Publication No.: WO 95/06636  
U.S. Serial No. not assigned  
Filed: not assigned  
For: 5-Arylindole Derivatives

The Examiner should note that Applicants have restricted the present application into five separate applications for the convenience to the Patent Office. Copies of the preliminary amendments for each case other than the present application are included herewith.


The Examiner is requested to consider carefully the claims of these applications in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither claimed nor obvious by the foregoing applications.

Please charge Deposit Account No. 16-1445 for any additional fees required under 37 C.F.R. 1.16 and 1.17. Two copies of this letter are enclosed.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: Nov 27, 1995

  
Grover F. Fuller Jr.  
Attorney for Applicant(s)  
Reg. No. 31,760

Pfizer Inc.  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-1390

1195260.GFF

3/91  
M.2  
(12/2)

201 1716 092 1201  
I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this 27th day of November, 1995.



*Grover F. Fuller Jr.*  
(Signature of person mailing)

Grover F. Fuller Jr.  
(Typed or printed name of person)

PATENT  
PC7851G  
#6  
1/18/96

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF: :  
JOHN EUGENE MACOR, ET AL. :

SERIAL NO. : 08/466,644 :

FILED: JUNE 6, 1995 :

FOR: INDOLE DERIVATIVES :  
-----

Examiner: Not yet  
assigned

Art Unit: Not yet  
assigned

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein makes available to the Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 CFR 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P.

3/91  
M.2  
(7/1)

1302.12).

A prompt and favorable response is earnestly solicited.

Date:

Nov. 27, 1995

Respectfully submitted,

Grover F. Fuller Jr.

Grover F. Fuller Jr.  
Attorney for Applicant(s)  
Reg. No. 31,760

Pfizer Inc.  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 573-1390  
1195244.GFF

3/91  
M.2  
(8/1)